Europe Bleeding Disorders Treatment Market Research Report - Segmented By Drug Class, Type & Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic & Rest of Europe) - Industry Analysis, Size, Share, Growth, Trends, & Forecasts (2024 to 2029)

Updated On: June, 2024
ID: 3231
Pages: 142

Europe Bleeding Disorders Treatment Market Size (2024 to 2029)

The bleeding disorders treatment market in Europe is anticipated to grow at a CAGR of 9.59% from 2024 to 2029, and the market size is anticipated to be worth USD 3.74 billion by 2029 from USD 2.37 billion in 2024.

The increasing population suffering from bleeding disorders across the European region is one of the key factors propelling the European market growth. Hemophilia, A patients lack protein, leading to a delay in blood clotting, as proteins are an essential part of the blood clotting mechanism. Based on these factors, hemophilia patients are more prone to bleeding disorders that require treatment, supporting market growth. In Europe, nearly 0.7% in every 10,000 people of the population suffer from a bleeding disorder which may also be life-threatening when the bleeding occurs in the brain and spinal cord.

In addition, the growing number of awareness programs by European governments and healthcare organizations is expected to promote regional market growth. The European government has taken several measures to spread awareness, especially among women and girls, about bleeding disorders to help them detect disorders early and have a healthy lifestyle through treatment. These awareness programs have been conducted during Bleeding Disorders Awareness month, which takes place in the month of march every year. In addition, the government lists food habits that help reduce or prevent bleeding disorders on many health-related applications and websites.

Furthermore, the rising adoption of technological developments in treatment procedures and medical devices for treating bleeding disorders is further favoring the market’s growth rate in Europe. Researchers are more focused on developing ways to treat bleeding disorders in an advanced way, such as pills, vaccines, and surgical procedures, which helps patients have fast recovery and fewer hospital stays. In addition, gene therapy is introduced as an advanced treatment for bleeding disorders which provides personalized medication and fast recovery from the issue.

However, high costs associated with the treatment procedures of bleeding disorders majorly hamper the regional market growth. The lack of proper reimbursement policies for the treatment, lack of skilled professionals, and lack of awareness among people regarding the treatment options further inhibit the growth of the European market. In addition, side effects associated with the drugs used in the treatment procedures hinder the market’s growth rate. It takes a long time to approve the drugs and vaccines, which impedes the bleeding disorder treatment market growth.

This research report on the European bleeding disorder treatment market has been segmented into the following categories.

By Drug Class: 

  • Fibrin Sealant
  • Desmopressin
  • Antibrinolytics
  • Recombinant Coagulation Factor Concentrates
  • Plasma Derived Coagulation Factor Concentrates

By Type:

  • vWD
  • Hemophilia A
  • Hemophilia B

By Country:

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

The European region accounted for the second largest share of the global market in 2021 and is anticipated to hold a considerable share in the global market during the forecast period owing to increasing healthcare awareness and the number of product and device approvals for advanced treatments. In addition, skilled professionals have conducted several clinical trials to approve products and devices used for treatment, reducing errors during the procedures.

Germany is one of the promising regional markets in the European region and is expected to occupy a notable share of the European market during the forecast period. The increasing investments primarily drive the market in Germany to conduct R&D around drugs and vaccines for bleeding disorder treatment. Healthcare providers in Germany suggest most patients with symptoms of the bleeding disorder get vaccinated to prevent the critical situation from repeating in their lifetime. Furthermore, in this region, children from an early age are advised to have a vaccine administered in case of any minor accident to help accelerate the clotting mechanism. In recent years, the German government has also started online registration for people suffering from hemophilia disorder. The stored data in the register helps the patient with the appropriate therapy for their bleeding disorder.

The UK is anticipated to hold a considerable share of the European region during the forecast period. In the United Kingdom, as per a recent survey, nearly 6,000 people in the UK have hemophilia. Haemophilia is often inherited, and the patients suffer from severe blood clots and different medical conditions. Therefore, these patients prefer to experiment with different types of treatment to save their life, which helps with the market's growth rate.


Johnson & Johnson Services, Inc., Novartis AG, Akorn Operating Company LLC, Bausch & Lomb Incorporated, AbbVie Inc., Prestige Consumer Healthcare Inc., Théa Laboratories, Wellona Pharma, Bayer AG, Zydus Group, OASIS Medical, Alcon and Santen Pharmaceutical Co., Ltd are some of the notable players in the European bleeding disorder treatment market.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1400

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample